The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-10-02 DOI:10.3324/haematol.2025.288675

Anna J T Smit,Niek G Van der Maas,Bronno Van der Holt,Yvette Van Norden,Erik Van Werkhoven,Annette Juul Vangsted,Paula F Ypma,Heleen A Visser-Wisselaar,Rossella Troia,Mario Boccadoro,Bob Löwenberg,Jeroen J W M Janssen,Gert J Ossenkoppele,Fredrik Schjesvold,Pieter Sonneveld,Sonja Zweegman,Jurjen Versluis,Jan J Cornelissen

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

贝叶斯中期分析在血液肿瘤随机II期和III期临床试验中的附加价值。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.